Sector News

GSK buys vaccine specialist GlycoVaxyn for $190m

February 12, 2015
Life sciences
GlaxoSmithKline (GSK) has taken control of Swiss company GlycoVaxyn in a $190m deal that bolsters its early vaccines pipeline.
 
GSK already owned a stake in GlycoVaxyn and had been working with the company since 2012 on the development of conjugate vaccines for bacterial infections. 
 
Buying the remainder of the company gives it a portfolio of early-stage candidates including an Escherichia coli vaccine in phase I trials and – more importantly – exclusive rights to the Swiss company’s platform technology for making new vaccine candidates.
 
GlycoVaxyn has developed a technique that makes it possible to produce conjugate vaccines in bacterial cells using bio-engineering, rather than using chemical conjugation, which makes it possible to develop vaccines against a broader range of bacterial infections. GSK said it could also make it easier to manufacture the vaccines.
 
In addition to the E. coli vaccine, GlycoVaxyn is also preparing to start clinical trials in the US of a vaccine against the severe diarrhoeal disease shigellosis in the coming weeks, backed by the Wellcome Trust, and its pipeline also includes candidates for pneumonia, Pseudomonas and Staphylococcus aureus.
 
Moncef Slaoui, who heads GSK’s vaccines business, said the deal was an “exciting opportunity” to develop a new generation of vaccines for serious bacterial infections, “for many of which there are currently no effective vaccines.”
 
Bacterial infections constitute a serious health issue as their ability to resist antibiotic treatment has grown significantly in recent years, so the role of vaccination is becoming increasingly important.
 
GSK’s vaccines unit accounts for around 14% of the company’s sales but saw turnover dip a little last year on increased competition and the suspension of a human papillomavirus (HPV) vaccination programme in Japan that affected its Cervarix product. 
 
The company has made vaccines a pillar of its strategy and last year agreed to take control of Novartis’ vaccine business (excluding flu vaccines) – including Bexsero for meningitis – in a swap for a portfolio of cancer drugs. That deal is due to close in the coming weeks and will consolidate GSK’s position as a leading vaccine player alongside Merck & Co and Sanofi.
 
Meanwhile, GSK has high hopes for its near-term vaccine pipeline, which include HZ/su for preventing shingles which generated positive phase III results last December, as well as a prophylactic vaccine for hepatitis C, a therapeutic vaccine for hepatitis B and a new tuberculosis shot. 
 
Source: PMLive

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend